Buprenorphine and Ketoconazole

Desk tier: Serious concern

Mechanism: strong CYP3A4 inhibition of clearance (↑ exposure)

“The concomitant use of buprenorphine and CYP3A4 inhibitors can increase the plasma concentration of buprenorphine, resulting in increased or prolonged opioid effects”

Suboxone (buprenorphine/naloxone) film, section 7 DRUG INTERACTIONS (Inhibitors of CYP3A4). DailyMed label

Open this pair in the desk

All pairs for Buprenorphine · Ketoconazole

Enzyme behind this pair: CYP3A4

Educational reference only. Not FDA-cleared. The Prescribing Information governs.